Metastatic Melanoma - Pipeline Review, H1 2015


Naperville, IL -- (SBWIRE) -- 03/04/2015 -- Reportstack, provider of premium market research reports announces the addition of Metastatic Melanoma - Pipeline Review, H1 2015 market report to its offering

Metastatic Melanoma - Pipeline Review, H1 2015


Metastatic Melanoma - Pipeline Review, H1 2015, provides an overview of the Metastatic Melanomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.

report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AB Science
AbbVie Inc.
Adaptimmune Limited
Agalimmune Ltd
Agenus, Inc.
Altor BioScience Corporation
Amgen Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
AVAX Technologies, Inc.
Bayer AG
Bioncotech Therapeutics S.L.
Bionomics Limited
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cancer Therapeutics CRC Pty Ltd
Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
Colby Pharmaceutical Company
CureTech Ltd.
Delcath Systems, Inc.
Digna Biotech, S.L.
DNA Therapeutics S.A.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Galapagos NV
Galectin Therapeutics, Inc.
GlaxoSmithKline plc
HanAll Biopharma Co., Ltd.
Immune Design Corp.
Immunophotonics Inc
ImmuRx, Inc.
Incyte Corporation
Life Science Pharmaceuticals, Incorporated
Lipotek Pty Ltd.
Luitpold Pharmaceuticals, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Momenta Pharmaceuticals, Inc.
Morphotek, Inc.
NeoStem, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
Pfizer Inc.
Philogen S.p.A.
Plexxikon Inc.
Polyphor Ltd.
Provectus Biopharmaceuticals, Inc.
Provenance Biopharmaceuticals Corp.
Reata Pharmaceuticals, Inc.
Recombio S.L
SBI Biotech Co., Ltd.
Scancell Holdings Plc
Takara Bio Inc.
Takeda Oncology
Ultimovacs AS
Vaxeal Holding SA
Vical Incorporated
WntResearch AB
ZIOPHARM Oncology, Inc.

Complete report is available

Roger Campbell
United States
Ph: 888-789-6604